WNX - Ticker AI Digest

Wellnex Life Limited 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (WNX) 1
WNX 06:01
Wellnex Life Limited
Q2 FY26 Quarterly Update and Appendix 4C
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Wellnex Life Limited Q2 FY26 Quarterly Update and Appendix 4C**
Wellnex Life Limited (ASX/AIMWNX) released its Q2 FY26 quarterly update and Appendix 4C on January 29, 2026, highlighting significant operational and financial improvements. Key takeaways include
1. **Financial Performance**
Operating cash outflow improved to $(0.16) million, a substantial reduction from $(2.98) million in Q1 FY26, driven by 31.5% quarter-on-quarter (QoQ) revenue growth and cost-cutting measures.
Customer cash receipts rose to $5.10 million, up from $4.54 million in Q1 FY26.
Total revenue increased to $7.1 million, with IP Licensing revenue surging by 1,000% to $3.3 million, offsetting a 25.5% decline in Brands revenue to $3.8 million due to strategic consolidation of non-core assets.
Gross profit grew by 16.7% to $2.1 million.
2. **Cash Position**
Quarter-end cash balance increased to $0.98 million, with $2.01 million in undrawn financing facilities available.
Total financing facilities stood at $11.65 million, with $9.65 million drawn.
3. **Strategic Focus**
The company continues its turnaround strategy, focusing on core brands like Pain Away, improving cash conversion, and strengthening the balance sheet.
Manufacturing and operating cash flows normalized after a one-off raw material purchase in Q1 FY26.
4. **Corporate Updates**
Payments of $0.36 million were made to related parties for directors fees, executive remuneration, and associated costs.
The Board remains optimistic about execution and engagement across the business, with efforts to enhance margins and reduce costs.
5. **Investor Engagement**
Executive Chairman Ash Vesali will host a live investor briefing on February 2, 2026, at 11 am (AEDT).
6. **Appendix 4C Highlights**
Net cash from operating activities improved to $(0.16) million.
Financing activities contributed $0.965 million in net cash.
Estimated cash available for future operations is $2.98 million, sufficient for approximately 18.3 quarters based on current cash outflows.
Wellnex Life remains committed to its strategic goals, with a focus on profitability and sustainable growth.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
WNX 06:56
Wellnex Life Limited
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 2
WNX 06:01
Wellnex Life Limited
Q2 FY26 Quarterly Update and Appendix 4C
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Wellnex Life Limited Q2 FY26 Quarterly Update and Appendix 4C**
Wellnex Life Limited (ASX/AIMWNX) released its Q2 FY26 quarterly update and Appendix 4C on January 29, 2026, highlighting significant operational and financial improvements. Key takeaways include
1. **Financial Performance**
Operating cash outflow improved to $(0.16) million, a substantial reduction from $(2.98) million in Q1 FY26, driven by 31.5% quarter-on-quarter (QoQ) revenue growth and cost-cutting measures.
Customer cash receipts rose to $5.10 million, up from $4.54 million in Q1 FY26.
Total revenue increased to $7.1 million, with IP Licensing revenue surging by 1,000% to $3.3 million, offsetting a 25.5% decline in Brands revenue to $3.8 million due to strategic consolidation of non-core assets.
Gross profit grew by 16.7% to $2.1 million.
2. **Cash Position**
Quarter-end cash balance increased to $0.98 million, with $2.01 million in undrawn financing facilities available.
Total financing facilities stood at $11.65 million, with $9.65 million drawn.
3. **Strategic Focus**
The company continues its turnaround strategy, focusing on core brands like Pain Away, improving cash conversion, and strengthening the balance sheet.
Manufacturing and operating cash flows normalized after a one-off raw material purchase in Q1 FY26.
4. **Corporate Updates**
Payments of $0.36 million were made to related parties for directors fees, executive remuneration, and associated costs.
The Board remains optimistic about execution and engagement across the business, with efforts to enhance margins and reduce costs.
5. **Investor Engagement**
Executive Chairman Ash Vesali will host a live investor briefing on February 2, 2026, at 11 am (AEDT).
6. **Appendix 4C Highlights**
Net cash from operating activities improved to $(0.16) million.
Financing activities contributed $0.965 million in net cash.
Estimated cash available for future operations is $2.98 million, sufficient for approximately 18.3 quarters based on current cash outflows.
Wellnex Life remains committed to its strategic goals, with a focus on profitability and sustainable growth.
WNX 06:01
Wellnex Life Limited
Market Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Wellnex Life Limited (ASX/AIMWNX) released a market update on January 16, 2026, highlighting significant financial and operational improvements in the first half of FY26 (H1 FY26). Key achievements include
1. **Financial Performance**
H1 FY26 EBITDA improved by $2.4 million compared to the prior year.
Gross margin increased from 22.8% to 31.3%.
December 2025 EBITDA rose by $0.7 million year-on-year, driven by reduced operating costs.
The company operated at breakeven by the end of Q2 FY26.
2. **Pain Away Brand**
Quarterly sales in Q2 FY26 reached $3.3 million, with a 7.6% improvement in gross margin.
Market share gains in Australia, with heat patches and roll-ons outperforming category growth.
New distribution partnerships secured, including Priceline and major pharmacy wholesalers, with upcoming launches at Costco Australia and New Zealand.
3. **Operational Focus**
Simplified operations and cost discipline measures have stabilized the business.
Contract manufacturing is being optimized for better productivity and sustainability.
4. **Outlook**
Wellnex enters H2 FY26 with improved stability and a clear turnaround trajectory.
The company remains focused on consistent performance and long-term shareholder value creation.
Executive Chairman Ash Vesali emphasized the company’s progress and commitment to sustainable growth, positioning Wellnex for continued success in 2026.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
WNX 06:01
Wellnex Life Limited
Q2 FY26 Quarterly Update and Appendix 4C
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Wellnex Life Limited Q2 FY26 Quarterly Update and Appendix 4C**
Wellnex Life Limited (ASX/AIMWNX) released its Q2 FY26 quarterly update and Appendix 4C on January 29, 2026, highlighting significant operational and financial improvements. Key takeaways include
1. **Financial Performance**
Operating cash outflow improved to $(0.16) million, a substantial reduction from $(2.98) million in Q1 FY26, driven by 31.5% quarter-on-quarter (QoQ) revenue growth and cost-cutting measures.
Customer cash receipts rose to $5.10 million, up from $4.54 million in Q1 FY26.
Total revenue increased to $7.1 million, with IP Licensing revenue surging by 1,000% to $3.3 million, offsetting a 25.5% decline in Brands revenue to $3.8 million due to strategic consolidation of non-core assets.
Gross profit grew by 16.7% to $2.1 million.
2. **Cash Position**
Quarter-end cash balance increased to $0.98 million, with $2.01 million in undrawn financing facilities available.
Total financing facilities stood at $11.65 million, with $9.65 million drawn.
3. **Strategic Focus**
The company continues its turnaround strategy, focusing on core brands like Pain Away, improving cash conversion, and strengthening the balance sheet.
Manufacturing and operating cash flows normalized after a one-off raw material purchase in Q1 FY26.
4. **Corporate Updates**
Payments of $0.36 million were made to related parties for directors fees, executive remuneration, and associated costs.
The Board remains optimistic about execution and engagement across the business, with efforts to enhance margins and reduce costs.
5. **Investor Engagement**
Executive Chairman Ash Vesali will host a live investor briefing on February 2, 2026, at 11 am (AEDT).
6. **Appendix 4C Highlights**
Net cash from operating activities improved to $(0.16) million.
Financing activities contributed $0.965 million in net cash.
Estimated cash available for future operations is $2.98 million, sufficient for approximately 18.3 quarters based on current cash outflows.
Wellnex Life remains committed to its strategic goals, with a focus on profitability and sustainable growth.
WNX 06:01
Wellnex Life Limited
Market Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Wellnex Life Limited (ASX/AIMWNX) released a market update on January 16, 2026, highlighting significant financial and operational improvements in the first half of FY26 (H1 FY26). Key achievements include
1. **Financial Performance**
H1 FY26 EBITDA improved by $2.4 million compared to the prior year.
Gross margin increased from 22.8% to 31.3%.
December 2025 EBITDA rose by $0.7 million year-on-year, driven by reduced operating costs.
The company operated at breakeven by the end of Q2 FY26.
2. **Pain Away Brand**
Quarterly sales in Q2 FY26 reached $3.3 million, with a 7.6% improvement in gross margin.
Market share gains in Australia, with heat patches and roll-ons outperforming category growth.
New distribution partnerships secured, including Priceline and major pharmacy wholesalers, with upcoming launches at Costco Australia and New Zealand.
3. **Operational Focus**
Simplified operations and cost discipline measures have stabilized the business.
Contract manufacturing is being optimized for better productivity and sustainability.
4. **Outlook**
Wellnex enters H2 FY26 with improved stability and a clear turnaround trajectory.
The company remains focused on consistent performance and long-term shareholder value creation.
Executive Chairman Ash Vesali emphasized the company’s progress and commitment to sustainable growth, positioning Wellnex for continued success in 2026.
WNX 06:56
Wellnex Life Limited
Director/PDMR Shareholding

AI Crunch

Single-Ticker AI Crunch
WNX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Wellnex Life Limited. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full WNX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for WNX on 2026-01-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
6645769
Enterprise Value
-
Public Float
53.2
Broker Target
-
Shares Out
69955476
Long Interest
-
Short Interest
-
Exchange
-
Currency Code
-
ISIN
AU0000162281
Market
None
Sector
Unknown
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
-
Net Debt
9712000.0
Cash
903000.0
EPS
-0.16
Net Income
-14737000.0
Revenue
16932000.0
Enterprise Value
-
Trailing PE
-
Forward PE
-
Price Sales TTM
0.2813
Price Book MRQ
1.2569
EV Revenue
0.6478
EV EBITDA
-

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
69955476
Public Hands
53.2
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
3
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit WNX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-01-29 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Wellnex Life Limited has fresh news flow feeding the chart narrative.
AI Charts Studio
WNX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-01-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast